Marinus Pharmaceuticals, Inc. - Special Call Transcript
Good morning, and welcome to the Marinus AES 2020 Investor Webinar. My name is Sasha Damouni, Head of Investor Relations. And as a reminder, today's presentation is being recorded, and a replay will be made available on the Marinus website at the conclusion of the event. (Operator Instructions)
We will begin with our forward-looking statement disclosure. Next, I would like to introduce our speakers for the day. On our agenda, we will be covering updates and AES data highlights during our corporate overview with our CEO, Dr. Scott Braunstein. Subsequently, Dr. Pestana Knight from the Cleveland Clinic will discuss CDKL5 deficiency disorder and our Phase III Marigold data. The presentation will be followed by a video with Dr. Orrin Devinsky, Director of the NYU Comprehensive Epilepsy Center and the Institute of Neurology and Neurosurgery at St. Barnabas; and Heidi Grabenstatter, Science Director of the International Foundation for CDKL5 Research, IFCR. We will then have a presentation of our CDD posters
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |